... is a risk of developing HIV resistance if SUSTIVA is underdosed. Bristol-Myers Squibb remains at the forefront of HIV/AIDS research and continues to pursue the development of treatment options for children and adults with HIV. Studies are ongoing ...
http://www.hivandhepatitis.com/hiv-aids/hiv-aids-topics/hiv-treatment/4098-fda-approves-efavirenz-sustiva-for-hiv-children-ages-3-months-to-3-years
http://www.hivandhepatitis.com/hiv-aids/hiv-aids-topics/hiv-treatment/4098-fda-approves-efavirenz-sustiva-for-hiv-children-ages-3-months-to-3-years
No comments:
Post a Comment